Results 191 to 200 of about 31,625 (241)

Role of Frailty in Assessing Eligibility for CAR T‐Cell Therapy in Haematology

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background and Objectives Frailty is a key consideration in determining whether a patient is robust enough for CAR T‐cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T‐cell therapy ...
Jennifer Clesham   +4 more
wiley   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi   +28 more
wiley   +1 more source

Case report: A retrospective serological analysis indicating human exposure to tick-borne relapsing fever spirochetes in Sonora, Mexico

open access: gold, 2019
Edwin Vázquez-Guerrero   +6 more
openalex   +1 more source

Relapsing fever <em>Borrelia</em> in California: a pilot serological study [PDF]

open access: gold, 2018
Marianne J Middelveen   +3 more
openalex   +1 more source

Erythema annulare centrifugum and Hodgkin lymphoma during pregnancy

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Valentine Horiot   +7 more
wiley   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy